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Abstract
Background: Routine electrocardiograms (ECGs) are not recommended for asymptomatic patients because the
potential harms are thought to outweigh any benefits. Assessment tools to identify high risk individuals may
improve the harm versus benefit profile of screening ECGs. In particular, people with unrecognized myocardial
infarction (UMI) have elevated risk for cardiovascular events and death.
Methods: Using logistic regression, we developed a basic assessment tool among 16,653 participants in the
REasons for Geographic and Racial Differences in Stroke (REGARDS) study using demographics, self-reported
medical history, blood pressure, and body mass index and an expanded assessment tool using information on 51
potential variables. UMI was defined as electrocardiogram evidence of myocardial infarction without a self-reported
history (n = 740).
Results: The basic assessment tool had a c-statistic of 0.638 (95% confidence interval 0.617 - 0.659) and included
age, race, smoking status, body mass index, systolic blood pressure, and self-reported history of transient ischemic
attack, deep vein thrombosis, falls, diabetes, and hypertension. A predicted probability of UMI > 3% provided a
sensitivity of 80% and a specificity of 30%. The expanded assessment tool had a c-statistic of 0.654 (95% confidence
interval 0.634-0.674). Because of the poor performance of these assessment tools, external validation was not
pursued.
Conclusions: Despite examining a large number of potential correlates of UMI, the assessment tools did not
provide a high level of discrimination. These data suggest defining groups with high prevalence of UMI for
targeted screening will be difficult.
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Background
Electrocardiogram (ECG) screening may identify previ-
ously unrecognized, treatable cardiac problems, such
as unrecognized myocardial infarction (UMI), thereby
improving health, but could also expose patients to side-
effects of treatment and lead to further testing with asso-
ciated costs and risks. Avoiding screening ECGs for low
risk individuals has been identified as one of the “top 5 ac-
tivities” for improving the quality of care in family and in-
ternal medicine [1]. Approximately 1-6% of the population
without a known history of myocardial infarction has evi-
dence of MI on ECG examination [2]. If UMIs are detected,
patients can be treated with medications that have demon-
strated benefits for secondary prevention such as aspirin,
beta-blockers, renin-angiotensin system blocking agents,
and statins [3]. If a subpopulation with high prevalence of
UMI could be identified, ECG screening could be targeted
efficiently. We therefore sought to develop assessment tools
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for UMI which could be used to identify populations where
ECG screening may be warranted.
Methods
Study population
The assessment tools were derived using baseline data from
the REasons for Geographic And Racial Differences in
Stroke (REGARDS) study population. REGARDS is a
nation-wide prospective cohort study of 30,239 men and
women aged 45 and older. Details of the study design and
recruitment have been previously published [4]. REGARDS
participants were recruited between January 2003 and
October 2007. Participants were identified using commer-
cially available lists with the goal of equal representation of
male and female and African-American and white partici-
pants. Geographically, participants were recruited to obtain
a population with 20% residing in coastal North Carolina,
South Carolina, and Georgia (Stroke Buckle), 30% from the
remaining areas of North Carolina, South Carolina, and
Georgia plus Tennessee, Mississippi, Alabama, Louisiana,
and Arkansas (Stroke Belt), and 50% from the other 40
contiguous US states and the District of Columbia [4].
Potential participants were contacted by telephone. After
verbal consent was obtained, data including demographic
and socioeconomic factors, medical history, psychosocial
factors, lifestyle factors, and cognitive function were col-
lected using computer-assisted telephone interviews (see
Additional file 1 for the data collection forms). Following
the interview, a technician conducted an in-home physical
exam, collected blood and urine, and measured anthropo-
metrics. Written informed consent was obtained during
the home visit. A food-frequency questionnaire and a fam-
ily history questionnaire were left with participants to be
completed and returned by mail. This research was
conducted in accordance with the Declaration of Helsinki.
The REGARDS study was approved by the Institutional Re-
view Boards of the University of Alabama at Birmingham,
the University of Vermont, Wake Forest University, and
the University of Cincinnati.
A modified 7-lead ECG was used until April 2004, and
after this point a standard 12-lead ECG was obtained [4].
Because 7-lead ECGs miss anterior and some lateral MIs,
we excluded 9,043 participants without a 12-lead ECG.
We additionally excluded participants who reported a his-
tory of myocardial infarction or revascularization proce-
dures (n = 2,919). Finally, we excluded individuals who
had missing data on potential correlates of UMI (n =
1,624) in order to conduct a complete-case analysis. After
these exclusions, there were 16,653 participants with data
available for development of the assessment tools.
Measurement of covariates
The REGARDS data collection instruments contained sev-
eral standard, previously validated questionnaires used in
health research, and additional items selected from ques-
tionnaires used in prior studies such as the Behavioral
Risk Factor Surveillance System, the Atherosclerosis Risk
In Communities Study, the Multi-Ethnic Study of Athero-
sclerosis, and the Greater Cincinnati/Northern Kentucky
Stroke Study [4]. Pilot testing was conducted to ascertain
the feasibility of the study processes in the target popula-
tion [4]. Participants self-reported information about
demographics and health behaviors. Urbanization was de-
termined by the census tract in which the participant re-
sided and was categorized as < 25% urban, 25%-75%
urban, and >75% urban. Educational attainment was cate-
gorized as less than high school, high school graduate,
some college, or college graduate or above. Income was
categorized < $20,000, $20,000-$34,999, $35,000-$74,999,
≥ $75,000 per year, or refused. Participants answered a
single question about current health insurance (yes or no).
Participants self-reported regular aspirin use (yes or no)
and time spent watching television or videos (none, 1–6 -
hours/week, 1 hour/day, 2 hours/day, 3 hours/day, or 4 or
more hours/day). They additionally reported information
about alcohol consumption, cigarette smoking, and exer-
cise. Alcohol consumption was classified as none, moder-
ate (0–7 drinks per week for women and 0–14 drinks per
week for men), or heavy (>7 drinks per week for women
and >14 drinks per week for men). Cigarette smoking was
categorized as current, past, and never. Exercise was cate-
gorized as none, 1–3 times per week, or 4 or more times
per week. Medication adherence was assessed using the 4-
item Morisky scale [5]. Each item in the Morisky scale
was considered separately.
Clinical measurements were obtained during the in-
home study visit by trained technicians. Body mass index
was calculated using measured height and weight. Two
blood pressure measurements were taken, and the values
averaged. The technicians obtained blood and urine
specimens which were processed and shipped to a cen-
tral laboratory. HDL cholesterol, LDL cholesterol, tri-
glycerides, C-reactive protein, white blood cell count,
and serum creatinine were measured in the blood sam-
ples. Albumin and creatinine were measured in the
urine. Estimated glomerular filtration rate (eGFR) was
calculated using the Chronic Kidney Disease Epidemi-
ology Collaboration (CKD-EPI) equation [6]. Because of
the nonlinear relationship of eGFR with adverse health
effects, we categorized it as ≥90 mL/min/1.73 m2, 60–
89 mL/min/1.73 m2, 45–59 mL/min/1.73 m2, 30–
44 mL/min/1.73 m2, and <30 mL/min/1.73 m2. Similarly,
the urinary albumin to creatinine ratio was categorized
as < 30 mg/g, 30–300 mg/g, and >300 mg/g. Heart rate
was measured by ECG. The 6-item screener for cogni-
tive function was administered in the telephone inter-
view [7]. A score of 4 or less was considered cognitive
impairment.
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Participants reported their history of stroke, transient
ischemic attack, deep vein thrombosis, peripheral vascu-
lar disease (amputation or surgery), dialysis for kidney
failure, falls, diabetes, hypertension, and dyslipidemia.
They also reported whether they were currently taking
antihypertensive medications. Family history of MI was
defined as report of MI in the mother or father of the
participant regardless of age at the time of the event. We
created variables for unrecognized diabetes, hyperten-
sion, and hyperlidipidemia. A participant was considered
to have unrecognized diabetes if they reported no prior
diagnosis, but had fasting serum glucose ≥126 mg/dL or
nonfasting serum glucose ≥200 mg/dL. Similarly, partici-
pants were considered to have unrecognized hyperten-
sion if they reported no prior diagnosis, but had systolic/
diastolic blood pressure ≥140/90 mmHg. Unrecognized
dyslipidemia was defined as no self-reported history and
total cholesterol ≥240 mg/dL, LDL cholesterol ≥ 160 mg/
dL, or HDL cholesterol ≤ 40 mg/dL.
Self-reported health scales included overall health sta-
tus (as excellent, very good, good, fair, or poor), the 4-
item Cohen’s Perceived Stress Scale [8], the 4-item Cen-
ter for Epidemiologic Studies Depression Scale (CESD-4)
[9], and the Medical Outcomes Study Short Form-12
(SF-12) from which physical and mental component
scores were calculated [10]. Participants self-reported
stroke symptoms, using the Questionnaire for Verifying
Stroke-Free Status [11], and whether they needed two or
more pillows to sleep at night or woke during the night
because of breathlessness.
Electrocardiogram reading and coding
ECGs performed during the in-home visit were read and
coded by a central reading center at Wake Forest University
by research staff blinded to other study data. Research staff
received initial training and certification followed by quar-
terly quality control examinations with retraining and
recertification when necessary. ECGs were read by a certi-
fied coder, followed by a review by a senior coder, and a
final review by the center PI (EZS) which focused on major
abnormalities. Disagreements were resolved through dis-
cussion between the coder, senior coder, and PI. When ne-
cessary, a senior coder who had not previously read the
ECG in question was asked to resolve the debate. Partici-
pants were considered to have UMI if they reported no his-
tory of MI, but had evidence of MI on ECG. This included
major Q/QS wave abnormalities by the Minnesota code
(MC) scheme (MC 1-1-X through 1-2-X) or smaller Q/QS
wave abnormalities (MC 1-3-X) with major ST-segment or
T-wave abnormalities (MC 4–1, 4–2, 5–1 or 5–2) [12].
Statistical analysis
We computed means and standard deviations or percent-
ages for each of the potential correlates for participants
with and without UMI. We additionally calculated each
participant’s Framingham risk score for coronary heart
disease [13]. The groups with and without UMI were
compared using linear regression for continuous variables
and χ2 tests for categorical variables. Using logistic regres-
sion, we calculated the crude odds ratio and the c-statistic
for each potential correlate. We used a logistic regression
approach to create the basic assessment tool. Basic demo-
graphics (age, sex, and race), smoking and alcohol con-
sumption, self-report of medical history, family history of
MI, and basic clinical measurements (body mass index
and blood pressure) available during routine office visits
were entered into a logistic regression model. For continu-
ous variables, the linear term and the square of the cen-
tered value were entered into the model. We then used a
backward selection procedure to create a more parsimoni-
ous model, requiring a p < 0.20 for a variable to remain.
Variables which were removed from the model through
backward selection were reconsidered, and if they im-
proved the c-statistic by ≥ 0.005, they were retained. The
model was used to calculate the predicted probability of
UMI for each participant, and a receiver operating charac-
teristic curve was constructed. We examined the perform-
ance of the UMI assessment tools in subgroups defined by
sex, race, and age (< 65 years or ≥ 65 years). The proced-
ure was repeated for the expanded set of potential corre-
lates described above including demographics, health
behaviors, clinical measurements, medical history, partici-
pant reported health scales, and participant reported
symptoms (expanded assessment tool). The ability of
the Framingham risk score for coronary heart disease to
discriminate between those with and without UMI was
evaluated using the c-statistic and receiver operating char-
acteristic curve. Analysis was conducted using SAS ver-




In the REGARDS study population without a reported
history of MI, 740 participants had UMI (4.4%). Charac-
teristics of the REGARDS study population considered
for the basic assessment tool are presented in Table 1 by
UMI status. The factors in the expanded assessment tool
are presented in Additional file 2: Table S1 by UMI sta-
tus. The average Framingham risk score for coronary
heart disease was 11.2% (standard deviation 10.2%) in
the participants with UMI and 8.4% (standard deviation
8.3%) in the participants without UMI.
Basic assessment tool
Established MI risk factors such as age, male sex,
cigarette smoking, diabetes, and hypertension were asso-
ciated with UMI in unadjusted analyses (Table 2). Age
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discriminated between those who did and did not have
UMI better than any other potential correlate, followed
by current use of antihypertensive medications, self-
reported hypertension, and systolic blood pressure. The
model with all of the potential correlates of UMI listed
in Table 2 had a c-statistic of 0.646 (95% CI 0.621-
0.672). The backward selection procedure resulted in an
assessment tool with 11 items: age, race, smoking status,
body mass index (linear and squared terms), systolic
blood pressure, and self-reported history of transient is-
chemic attack, deep vein thrombosis, falls, diabetes, and
hypertension. None of the omitted variables improved
the c-statistic by more than 0.005 when they were added
back to the model. The c-statistic for the basic assess-
ment tool was 0.638 (95% CI 0.617 - 0.659, p < 0.001
for test of no discrimination) (Figure 1). In order to
detect at least 80% of individuals with UMI using the
basic assessment tool, everyone with a predicted prob-
ability > 3% would need to undergo ECG screening. In
the REGARDS study population, 70% of participants had
a > 3% predicted probability. The > 3% predicted risk
threshold corresponded to a specificity of 30%. A pre-
dicted probability of UMI of 5% maximized the sum of
sensitivity and specificity and corresponded to a sensitiv-
ity of 50% and a specificity of 69%; 32% of REGARDS
participants had a predicted probability > 5% (Figure 2).
Results were similar in subgroups defined by age (< 65 -
years or ≥ 65 year), sex, and race.
Expanded assessment tool
Unadjusted associations between the expanded set of
covariates and presence of UMI are presented in
Additional file 3: Table S2. The model with all of the
expanded set of potential correlates of UMI had a
c-statistic of 0.677 (95% CI 0.650-0.704). The backward
selection procedure produced an expanded assessment
tool with 15 items (age, race, income, smoking status,
self-reported hypertension, unrecognized dyslipidemia,
perceived stress score, waking at night due to breathless-
ness, body mass index and body mass index squared,
Table 1 Characteristics considered in the basic assessment tool by unrecognized myocardial infarction status
UMI No MI p-value
(n = 740) (n = 15,913)
Age (years) 66.7 (9.9) 63.2 (9.6) <0.001
Female (%) 61.8 65.8 0.03
African-American (%) 42.2 41.3 0.66
Smoking status (%) 0.003
Never smoker 45.1 50.0
Past smoker 36.8 35.9
Current smoker 18.1 14.1




History of stroke (%) 6.8 4.3 0.002
History of transient ischemic attack (%) 4.9 3.2 0.01
History of deep vein thrombosis (%) 4.6 4.6 0.93
History of peripheral vascular disease (%) 1.6 1.1 0.24
History of dialysis (%) 0.4 0.2 0.17
History of falls (%) 18.7 15.5 0.02
Self-reported diabetes (%) 24.6 18.9 <0.001
Self-reported hypertension (%) 68.0 54.4 <0.001
Self-reported dyslipidemia (%) 50.1 49.3 0.64
Family history of myocardial infarction (%) 31.1 33.7 0.13
Systolic blood pressure (mmHg) 130 (18) 126 (16) <0.001
Diastolic blood pressure (mmHg) 77 (10) 76 (10) 0.12
Current use of antihypertensives (%) 64.0 49.5 <0.001
Body mass index (kg/m2) 29.0 (6.9) 29.4 (6.3) 0.10
Numbers in table are mean (standard deviation) or percent. UMI Unrecognized myocardial infarction; MI Myocardial infarction.
Levitan et al. BMC Cardiovascular Disorders 2013, 13:23 Page 4 of 8
http://www.biomedcentral.com/1471-2261/13/23
HDL cholesterol squared, systolic blood pressure, albu-
min to creatinine ratio, heart rate, and heart rate
squared) and a c-statistic of 0.654 (95% CI 0.634-0.674,
p < 0.001 for test of no discrimination) (Figure 1). To ob-
tain a sensitivity of 80%, a > 3% predicted probability
threshold would be needed, which corresponded to a
specificity of 34%.
Comparison with the Framingham risk score for coronary
heart disease
The c-statistic for identifying participants with UMI using
the Framingham risk score for coronary heart disease was
0.587 (95% CI 0.566-0.609) (Figure 1). If participants con-
sidered high risk of coronary heart disease (Framingham
risk score of 20% or above) were screened, 17% of UMIs
would be detected (sensitivity) while 91% of those without
UMI would not receive ECG (specificity).
Discussion
In the current study, we attempted to develop tools
for identifying individuals with an elevated probability
of UMI as determined by ECG among those without a
self-reported history of MI. Such a tool would allow
targeting of ECG screening for UMI to higher-risk indi-
viduals. However, neither the tool built using potential
correlates routinely collected nor the expanded tool
which considered a large battery of variables had a c-
statistic greater than 0.7, a widely used guideline for
Table 2 Odds ratios and c-statistics for unrecognized myocardial infarction in the basic assessment tool
Univariate
c-statistic
Odds ratio (95% CI) Odds ratio (95% CI)
Unadjusted Backwards selection*
Age (10 years) 0.602 1.45 (1.35-1.57) 1.38 (1.27-1.49)
Sex 0.520
Male 1.00 (reference) –
Female 0.84 (0.72-0.98) –
Race 0.504
White 1.00 (reference) 1.00 (reference)
African-American 1.03 (0.89-1.20) 0.93 (0.79-1.09)
Smoking status 0.531
Never smoker 1.00 (reference) 1.00 (reference)
Past smoker 1.13 (0.96-1.33) 1.08 (0.92-1.28)
Current smoker 1.42 (1.16-1.75) 1.60 (1.29-1.98)
Alcohol use 0.509
None 1.00 (reference) –
Moderate 0.97 (0.82-1.13) –
Heavy 0.75 (0.49-1.15) –
History of stroke 0.512 1.60 (1.19-2.16) –
History of transient ischemic attack 0.509 1.58 (1.11-2.26) 1.18 (0.82-1.69)
History of deep vein thrombosis 0.500 1.02 (0.72-1.45) 0.89 (0.63-1.28)
History of peripheral vascular disease 0.502 1.43 (0.79-2.57) –
History of dialysis 0.501 2.24 (0.68-7.36) –
History of falls 0.516 1.24 (1.03-1.51) 1.15 (0.95-1.40)
Self-reported diabetes 0.528 1.40 (1.18-1.66) 1.25 (1.04-1.50)
Self-reported hypertension 0.568 1.78 (1.52-2.09) 1.56 (1.32-1.86)
Self-reported dyslipidemia 0.504 1.04 (0.89-1.20) –
Family history of myocardial infarction 0.513 0.89 (0.76-1.04) –
Systolic blood pressure (10 mmHg) 0.564 1.15 (1.10-1.19) 1.08 (1.03-1.13)
Diastolic blood pressure (10 mmHg) 0.510 1.06 (0.98-1.15) –
Current use of antihypertensives 0.572 1.81 (1.55-2.12) –
Body mass index (5 kg/m2) 0.524 0.95 (0.90-1.01) 0.89 (0.83-0.96)
Body mass index squared (5[kg/m2]2) 0.521 1.004 (1.001-1.007) 1.008 (1.003-1.012)
* C statistic for backward selection model = 0.638 (95% CI 0.617-0.659).
Levitan et al. BMC Cardiovascular Disorders 2013, 13:23 Page 5 of 8
http://www.biomedcentral.com/1471-2261/13/23
adequate discrimination [14]. Furthermore, the test char-
acteristics were such that a reasonably high sensitivity
required a very low specificity.
Previous studies have found that coronary heart dis-
ease risk factors such as older age, male sex, diabetes,
hypertension, dyslipidemia, and smoking are associated
with UMI [15]. While the traditional coronary heart dis-
ease risk factors were associated with prevalent UMI in
the REGARDS study population, they did not discrimin-
ate well between participants with and without UMI. For
incident coronary heart disease, the Framingham risk
score, which incorporates many of the risk factors and is
recommended for use in the general United States popu-
lation without known cardiovascular disease, has been
shown to have a c-statistic greater than 0.7 in many, but
not all, populations [16]. In the current study, the c-
statistic for UMI associated with the Framingham risk
score was 0.587. The Framingham Risk Score is a vali-
dated risk score for incident coronary heart disease. Its
use for prevalent UMI is unvalidated. The AUC of FRS
in lower than expected but this should be interpreted
with caution. The difference in the ability to discriminate
between people who will develop coronary heart disease
and those who will not and the ability to discriminate
between people with prevalent UMI and those without
prevalent UMI may be because of the variety of pro-
cesses that are involved in having UMI. An ischemic in-
jury causing Q-waves must occur but go unrecognized
by the individual or the individual’s health care pro-
viders or both. Then factors related to survival with MI
come into play in order to become a member of the
REGARDS study. Finally, ECG abnormalities are known
to resolve over time in some people [17]; the partici-
pants in this study considered to have UMI were only
those with persistent ECG indications of MI. The com-
plicated pathway to UMI may hinder identification of
populations with high prevalence of UMI.
The current study focused on the c-statistic as the
metric of discrimination for the UMI assessment tools.
C-statistics are known to be higher in the population in
which they are derived than in independent populations,
and therefore it is customary to validate the assessment
tools in external populations. In the current study, this
step was not taken because of the poor performance of
the tools in the derivation cohort. The difference in c-
statistics between the UMI assessment tools, which were
developed in the REGARDS study, and the Framingham
risk score for coronary heart disease would likely have
been smaller in an independent population. We did not
examine calibration metrics in this study because, in the
absence of acceptable discrimination, even a very well-
calibrated assessment tool would not add important in-
formation to the decision of whether or not to screen
for UMI.
The major strengths of this study include the large, di-
verse REGARDS study population and the wide variety
of potential correlates which have been measured. There
are also limitations of this study. We used ECG criteria
for defining UMI, though Q-waves on ECG are absent in
some patients with documented MI [17], may be due to
conditions other than MI [18,19], and do not agree well
with myocardial scars detected on cardiac magnetic res-
onance imaging with gadolinium contrast [19]. The in-
ability to detect UMI not associated with Q-waves is an
inherent limitation of the ECG method for detection of
Figure 1 Receiver operating characteristic curves for the
unrecognized myocardial infarction assessment tools. Basic
assessment tool (solid black line), expanded assessment tool (solid
gray line), and Framingham risk score for coronary heart disease
(dashed black line).
Figure 2 Test characteristics of the unrecognized myocardial
infarction basic assessment tool. Sensitivity (solid black line),
specificity (solid gray line), and sum of sensitivity and specificity
(dashed black line).
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UMI; however, the use of the MC scheme reduces the
concern about Q-waves due to other conditions which
take precedence over MI in the coding system [12]. We
believe that ECG would be more appropriate for screen-
ing in a general population than cardiac magnetic reson-
ance imaging with gadolinium contrast because of the
greater availability, lower cost, and time needed for
ECGs, and the potential for serious adverse reactions to
gadolinium contrast.
We relied on self-report to identify individuals with rec-
ognized MI and history of coronary heart disease. Previ-
ous studies have shown that some participants report MI
when there is no clinical record of MI, and others may re-
port no history of MI when a diagnosis of MI has been
documented [20,21]. Some of the participants in the
REGARDS study population who we considered to have
UMI may have a known MI from the perspective of their
healthcare providers. While the patient-centered approach
we took was designed to simulate patient encounters with
physicians, it is possible that lack of accuracy in self-
report of MI makes an UMI assessment tool impractical
in the clinical setting. Many of the potential correlates of
UMI were also self-reported. Some of the correlates are by
definition self-reported, such as self-rated health, per-
ceived stress, and depression symptoms, but different ap-
proaches may be more reliable for other covariates, such
as prior medical history. In these cases, reliance on self-
reported data could lead to increased error and an under-
estimation of the ability of these factors to discriminate
between individuals with and without UMI. Finally, ECG,
blood pressure, and biomarkers were measured during a
single in-home visit and are subject to measurement error
which could also lead to underestimation of the ability to
discriminate between individuals with and without UMI.
However, these measurements were made using a research
protocol, which may be more reliable than measures
obtained in routine clinical practice; this may result in
worse performance of the tool in clinical care settings than
we report here.
Conclusions
Although the assessment tools for UMI performed sig-
nificantly better than chance, they demonstrated low
levels of discrimination. Given the test properties of the
assessment tools, they are unlikely to be useful in clinical
practice. These data suggest that it will be difficult to de-
fine a population with a high prevalence of UMI for
targeted ECG screening.
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